In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

[1]  Yibin Wang,et al.  Response by Zhang et al to Letter Regarding Article, “Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19” , 2020, Circulation research.

[2]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[3]  G. Mancia,et al.  Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.

[4]  A. Troxel,et al.  Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 , 2020, The New England journal of medicine.

[5]  Junyan Han,et al.  Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study. , 2020, Hypertension.

[6]  Giuseppe Lippi,et al.  Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis , 2020, Clinica Chimica Acta.

[7]  Jian Chen,et al.  Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.

[8]  Qingbo Xu,et al.  Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.

[9]  G. Lippi,et al.  Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 , 2020, Mayo Clinic Proceedings.

[10]  C. Rapezzi,et al.  2019 CORONAVIRUS: What are the implications for cardiology? , 2020, European journal of preventive cardiology.

[11]  G. Lippi,et al.  Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. , 2020, Polish archives of internal medicine.

[12]  G. Marín.  Facts and reflections on COVID-19 and anti-hypertensives drugs. , 2020, Drug discoveries & therapeutics.

[13]  James H Diaz,et al.  Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 , 2020, Journal of travel medicine.

[14]  J. Meng,et al.  Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension , 2020, Emerging microbes & infections.

[15]  L. Burrell,et al.  Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease , 2018, PloS one.

[16]  J. Kalman,et al.  Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  D. Fedson.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. , 2016, Annals of translational medicine.

[18]  P. Macdonald,et al.  Myocardial infarction increases ACE2 expression in rat and humans. , 2005, European heart journal.

[19]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[20]  Nigel M Hooper,et al.  ACE2: from vasopeptidase to SARS virus receptor , 2004, Trends in Pharmacological Sciences.